Compare JFrog Ltd. Ordinary Shares (FROG) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JFrog Ltd. Ordinary Shares vs Novavax Inc — how do they compare? JFrog Ltd. Ordinary Shares trades at $97.61 (market cap $12.10B), while Novavax Inc trades at $10.99 (market cap $1.85B). The key difference: JFrog Ltd. Ordinary Shares is far larger — about 6.5× Novavax Inc's market cap, and JFrog Ltd. Ordinary Shares is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JFrog Ltd. Ordinary Shares for 0 Days and Novavax Inc for 59 Days on average.
| FROG | NVAX | |
|---|---|---|
Market Cap | $12.10B | $1.85B |
Volume | 773,694 | 8,362,562 |
Sector | Technology | Health |
52-Week High | $104.03 | $12.56 |
52-Week Low | $34.75 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $11.29B | $1.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $11.01, down 2.74% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported strong revenue of $1.12B in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Recent news highlights the company's pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in major markets.
Investment outlook remains speculative with analyst consensus heavily favoring Buy ratings (73.92%) but fundamental risks persist including negative cash flow trends and high debt levels. The stock offers potential upside from partnership expansions but faces significant execution and competitive risks in the biopharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JFrog Ltd. Ordinary Shares
JFrog provides software supply chain tools that help developers manage, secure, and distribute software packages. Its platform is used across development and deployment workflows.
Read more on FROG →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
